Gracell Biotechnologies Inc. has closed a $100 million series C financing round to advance its CAR T-cell therapy candidates, including autologous product candidate, GC-012F, and allogeneic product candidate, GC-027. Both candidates are in investigator-initiated phase I trials in China.
When entrepreneurs and emerging businesses raise seed capital for a new business or generate funding for business growth, they often turn to the exempt offering framework under the Securities Act. However, when doing so, they are faced with a confusing and complex system that must be navigated. To simplify the process, the SEC has announced that it is amending its rules that govern offering exemptions, which small and medium-sized business rely on to raise capital.
Biopharmas raising money in public or private financings, including: Aquestive, Cancer Genetics, Forte, Fountain Healthcare, Inhibikase, Jiya, Massive Bio, Quantum Genomics, Scholar Rock, Ultragenyx.
The dramatic increase in COVID-19 infections in Europe and the U.S., combined with information overload surrounding the lead up to the Nov. 3 contentious U.S. presidential election, was more than enough to send investors to the sidelines in October.
LONDON – Former CEO of Novartis AG Joe Jimenez is emerging back into the limelight as founder and managing director of Aditum Bio, a new $135 million venture capital fund set up to create five to six companies to take forward early stage compounds in-licensed from pharma.
Gracell Biotechnologies Inc. has closed a $100 million series C financing round to advance its CAR T-cell therapy candidates, including autologous product candidate, GC-012F, and allogeneic product candidate, GC-027. Both candidates are in investigator-initiated phase I trials in China.
RSS
